


Selective Synthesis of Substituted Pyrrole-2-phosphine Oxides and -phosphonates from 2*H*-Azirines and Enolates from Acetyl Acetates and Malonates

Francisco Palacios,* Ana M. Ochoa de Retana, and Ander Vélez del Burgo

Departamento de Química Orgánica I, Facultad de Farmacia, Centro de Investigaciones y Estudios Avanzados "Lucio Lascaray", Universidad del País Vasco, Apartado 450, 01080 Vitoria, Spain

S Supporting Information




ABSTRACT: A simple and efficient selective synthesis of 1*H*-pyrrole-2-phosphine oxides **3** and -phosphonates **7** by addition of enolates derived from acetyl acetates to 2*H*-azirinyolphosphine oxide **1** and -phosphonate **6** is reported. Nucleophilic addition of enolates derived from diethyl malonate to 2*H*-azirines **1** and **6** led to the formation of functionalized 2-hydroxy-1*H*-pyrrole-5-phosphine oxide **9** and -phosphonate **10**, while vinylogous α -aminoalkylphosphine oxides **14** and -phosphonate **15** may be obtained from azirines and the enolate derived from diethyl 2-phenylmalonate. Ring closure of vinylogous derivatives **14** and **15** in the presence of base led to the formation of 1,5-dihydro-3-pyrrolin-2-ones containing a phosphine oxide **17** or a phosphonate group **18**.

INTRODUCTION

2*H*-Azirine ring systems represent an important class of compounds because of their high reactivity.¹ They can be used as key intermediates in organic synthesis in the preparation of heterocycles^{2a–e} and acyclic functionalized amino derivatives,^{2f–h} since any of the three bonds of the azirine ring can be cleaved, depending on the experimental conditions used. On the other hand, pyrroles³ are important heterocycles broadly used in material science⁴ and not only can be found in naturally occurring and biologically important molecules⁵ but also are important intermediates in the synthesis of natural products;⁶ some of the recently isolated pyrroles have been found to exhibit considerable cytotoxicity and function in multidrug resistant (MDR) reversal^{7a} and antimycobacterial activity.^{7b} In this context, 2-silyloxy-pyrroles **I** (Scheme 1, R =

Scheme 1



SiR₃) and α,β -unsaturated γ -butyrolactams or 1,5-dihydro-3-pyrrolin-2-ones **II** (Scheme 1) demonstrated in the last years a wide use as efficient donors in diastereoselective and in enantioselective aldol reactions and related processes such as Mannich and Michael reactions.^{8,9} For these reasons, although many methods have been devised for their preparation¹⁰ the

design and development of new methods of synthesis of substituted pyrroles continues to be a challenge.¹¹


The importance of azaheterocyclic phosphonates in synthetic, agrochemical, and medicinal chemistry has been well-documented¹² because it is known that phosphorus substituents regulate important biological functions¹³ and that molecular modifications involving the introduction of organophosphorus functionalities in simple synthons could be very interesting because they can be useful substrates for the preparation of biologically active compounds. However, very little information is reported about the properties of phosphonopyrroles¹² **III** (Scheme 1) undoubtedly due to the fact that there is no general method for their preparation. Only a few examples have been reported for the synthesis of 2-phosphonopyrroles (**III**) as shown in Scheme 2 involving either the use of heterocyclic precursors such as the aromatization of 3-oxo-2-phosphonate pyrrolidines (**IV**)¹⁴ and the phosphorylation of pyrroles (**V**)^{12a} or the use of acyclic substrates such as the [3 + 2] cycloaddition of iminomethylphosphonates (**VI**) with acetylenic compounds¹⁵ or the ring-closing metathesis of functionalized aminophosphorus derivatives (**VII**).¹⁶

We describe new methods for the preparation of phosphorus-substituted nitrogen heterocycles¹⁷ including *N*-hydroxypyrrole derivatives^{17d} from functionalized phosphine oxides and phosphonates and the synthetic uses of amino-phosphorus derivatives as starting materials for the synthesis of

Received: September 20, 2011

Published: October 14, 2011

Scheme 2




acyclic compounds¹⁸ and phosphorus-containing heterocycles.¹⁹ Likewise, we reported the preparation of 2*H*-azirinephosphine oxides **VIII** (R = Ph) and -phosphonates **VIII** (R = OEt, Scheme 2) through base-mediated Neber reaction of β -ketoimide tosylates²⁰ and their use for the synthesis of aminophosphorus derivatives,²¹ and phosphorylated pyrazines,^{22a} oxazoles,^{22b,c} or aziridines.^{22d} Continuing with our interest in the chemistry of small strained nitrogen heterocycles, we report here a new strategy for the preparation of functionalized pyrroles (**III**) containing phosphorus substituents such as a phosphine oxide (**III**, R = Ph) or a phosphonate group (**III**, R = OEt) by the selective addition of enolates derived from acetylacetates and malonates to phosphorylated azirines **VIII** (Scheme 2).

RESULTS AND DISCUSSION

Selective Addition of Enolates Derived from Acetylacetates to 2*H*-Azirines. Because of the strain of the three-membered ring, the electrophilic character of the C–N double bond is higher than in a normal imine, and azirines react with nucleophiles at the N–C3 double bond to produce aziridines.¹ Reaction of 2*H*-azirinephosphine oxide **1a** (R = Ph, R¹ = CH₃) with methyl 2-oxobutanoate **2a** (R² = CH₃) and NaH in THF led to the formation of 4-methoxycarbonyl-3,5-dimethyl-1*H*-pyrrol-2-ylphosphine oxide **3a** (R = Ph, R¹ = R² = CH₃; Scheme 3, Table 1, entry 1). In the ³¹P NMR spectrum the

Scheme 3

Table 1. Substituted Pyrroles **3** and **7**

entry	compd	R	R ¹	R ²	yield ^a (%)
1	3a	Ph	CH ₃	CH ₃	60
2	3b	Ph	CH ₃	C ₂ H ₅	60
3	3c	Ph	C ₂ H ₅	CH ₃	75
4	7a	OEt	CH ₃	CH ₃	60
5	7b	OEt	Ph	CH ₃	95

^aYield of isolated purified compounds **3** and **7** from azirines **1** or **6**.

phosphine oxide group of this substituted pyrrole **3a** resonated at $\delta_p = 21.9$ ppm, while singlets at $\delta_H = 1.89$ (⁴J_{PH} = 1.5 Hz) and 2.42 ppm for both methyl groups in the ¹H NMR were observed. The formation of pyrrole **3a** suggests the approach of the enolate derived from acetyl acetate **2** to the C=N double bond of the azirine followed by ring-opening of the three membered heterocycle **4**, cyclization to the 5*H*-pyrrole **5**, and subsequent prototropic rearrangement to aromatic pyrrole **3**.

Similarly, pyrrole-phosphine oxides **3b,c** were obtained (Scheme 2, Table 1, entries 2 and 3) when the reaction of azirine **1a** (R = Ph, R¹ = CH₃) was performed with the enolate derived from ethyl 2-oxobutanoate **2b** (R² = C₂H₅) in the presence of NaH in THF or by the reaction of azirine **1b** (R = Ph, R¹ = C₂H₅) with the enolate derived from methyl 2-oxobutanoate **2a** (R² = CH₃). This process could also be extended to 2*H*-azirines derived from phosphonates **6**. Treatment of 3-methyl- (**6a**) (R = OEt, R¹ = CH₃) and 3-phenyl-2*H*-azirine (**6b**) (R = OEt, R¹ = Ph) with the enolate derived from methyl 2-oxobutanoate **2a** gave 1*H*-pyrrol-2-yl phosphonates **7a,b** (Scheme 2, Table 1, entries 4 and 5). Pyrrole derivatives³ have been also obtained by ring expansion of 3-vinyl 2*H*-azirines²³ or by reaction of azirines with dimethyl acetylenedicarboxylate.²⁴ However, our strategy describes, as far as we know, the first synthesis of 1*H*-pyrrole-2-phosphonates and -phosphine oxides from azirines.

Selective Addition of Enolates Derived from Diethyl Malonates to 2*H*-Azirines. Reaction of enolates derived from β -diesters to 2*H*-azirines was also studied in order to test if these nucleophiles could give a new entry to substituted phosphorylated pyrrole derivatives. For this reason, we explored the reaction of 2*H*-azirinephosphine oxides **1** and -phosphonates **6** with the enolates derived from malonates. Treatment of 3-methyl-2*H*-azirine-2-yl-diphenylphosphine oxide **1a** (R = Ph, R¹ = CH₃) and 3-ethyl-2*H*-azirine-2-ylphosphonate **6b** (R = OEt, R¹ = C₂H₅) with enolate derived from diethyl malonate **8a** (R³ = H) and NaH at 0 °C led exclusively to the formation of 2-hydroxy-1*H*-pyrroles with a phosphine oxide **9** (R = Ph) (Scheme 4, Table 2, entries 1 and 2) or a phosphonate in the 5 position **10** (R = OEt) (Scheme 4, Table 2, entry 3).

The formation of these hydroxypyrrole derivatives **9** and **10** may be explained by nucleophilic addition of the enolate from diethyl malonate to the imine bond of the azirines (Scheme 4) followed by ring-opening of the aziridine intermediate **11** (R³ = H) and [1,3] hydrogen rearrangement from the carbon to the nitrogen atom with formation of intermediate **12**, intramolecular cyclization of which may give 1,5-dihydro-3-pyrrolin-2-one **13**. The aromatization of these heterocycles **13** may give the corresponding pyrrole derivatives **9** and **10**, favored by the presence of an ethoxycarbonyl group in position 3. A procedure for the synthesis of 3-hydroxypyrrole-phosphonates **III** (see Scheme 2, vide supra) by the aromatization of 3-oxo-2-phosphonate pyrrolidines (**IV**) has

Scheme 4




Table 2. Heterocycles Obtained from Azirines and Enolates Derived from Malonates

entry	compd	R	R ¹	yield ^a (%)
1	9a	Ph	CH ₃	60 ^b
2	9b	Ph	C ₂ H ₅	72 ^b
3	10	OEt	C ₂ H ₅	65 ^b
4	14a	Ph	CH ₃	50 ^b
5	14b	Ph	C ₂ H ₅	60 ^b
6	15	OEt	CH ₃	45 ^b
7	17a	Ph	CH ₃	83 ^c
8	17b	Ph	C ₂ H ₅	70 ^c
9	18	OEt	CH ₃	94 ^c

^aYield of isolated purified compounds 9, 10, 14, 15, 17, and 18. ^bFrom azirines 1 and 6. ^cFrom vinylogous derivatives 14 and 15.

been reported.¹⁴ However, this process reported here describes, as far as we know, the first the synthesis of 2-hydroxy-pyrroles with a phosphine oxide 9 or a phosphonate in the 5 position 10.

However, a different behavior was observed by the reaction of 2*H*-azirinyphosphine oxides 1 and -phosphonates 6 with the enolate derived from a 2-substituted malonate. Treatment of 2*H*-azirin-2-yl-diphenylphosphine oxide 1a,b (R = Ph) and 2*H*-azirin-2-yl-phosphonate 6a (R = OEt) with enolate derived from diethyl 2-phenylmalonate 8b (R³ = Ph) and NaH at 0 °C led exclusively to the formation of vinylogous α -aminoalkylphosphine oxides 14 (R = Ph) (Scheme 4, Table 2, entries 4 and 5) or -phosphonate 15 (R = OEt) (Scheme 4, Table 2, entry 6). The selective nucleophilic addition of the enolate of 2-phenyl diethyl malonate to the imine bond of the azirines may explain the formation of adduct 11. Ring-opening of the aziridine intermediate 11 with concomitant [1,5] rearrangement of the carboxylate group to the nitrogen atom may give the corresponding vinylogous α -aminoalkylphosphine oxides 14 and -phosphonate 15.²⁵ Vinylogous α -aminophosphorus derivatives²⁶ 14 and 15 are isosteres of biologically active α -vinylglycines.²⁷

Thermal treatment of vinylogous α -aminoalkylphosphine oxides 14 and -phosphonate 15 with NaH in reflux THF led to

the formation of 1,5-dihydro-3-pyrrolin-2-ones or 1*H*-pyrrol-2(*SH*)-ones with a phosphine oxide 17 (R = Ph) (Scheme 4, Table 2, entries 7 and 8) or a phosphonate in the 5 position 18 (R = OEt) (Scheme 4, Table 2, entry 9). The formation of these pyrrole derivatives 17 and 18 may be explained by cyclocondensation of vinylogous derivatives 14 and 15 in the presence of NaH, formation of *N*-protected 1,5-dihydro-3-pyrrolin-2-ones 19, and deprotection of these heterocycles 19 (Scheme 4). This process describes the first synthesis of 1,5-dihydro-3-pyrrolin-2-ones or 1*H*-pyrrol-2(*SH*)-ones 17 and 18 with a phosphorus-containing functional group.

CONCLUSION

In conclusion, this account describes a simple, mild, and convenient strategy for the selective synthesis of 1*H*-pyrroles 3 and 7 containing in the 2 position a phosphine oxide or a phosphonate group by addition of enolates derived from β -keto esters to 2*H*-azirinyphosphine oxide 1 and -phosphonate 6, while the addition of enolates derived from diethyl malonate to 2*H*-azirines 1 and 6 led to the formation of functionalized 2-hydroxy-1*H*-pyrrole-5-phosphine oxide 9 and -phosphonate 10. However, vinylogous α -aminoalkylphosphine oxides 14 and -phosphonate 15 may be obtained from azirines and the enolate derived from diethyl 2-phenylmalonate. Vinylogous α -amino-phosphorus derivatives are scarcely studied and prepared²⁶ and are isosteres of biologically active α -vinylglycines.²⁷ Basic cyclocondensation in the presence of a base (NaH) of these substrates 14 and 15 gives 1,5-dihydro-3-pyrrolin-2-ones 17 and 18 with a phosphine oxide or a phosphonate group in 5 position. Substituted pyrroles are important building blocks in organic synthesis,^{3–7} and in recent years, some specific pyrrole derivatives such as oxypyrroles I or 1,5-dihydro-3-pyrrolin-2-ones II (Scheme 1) gained great relevance in diastereoselective and enantioselective preparative organic synthesis,^{8–11} while phosphorus substituents regulate important biological functions,¹³ and then molecular modifications involving the introduction of organophosphorus functionalities in pyrrole derivatives could be interesting because these new substituted five membered heterocycles may be useful substrates for the

preparation of biologically active compounds of interest in medicinal chemistry.¹²

■ EXPERIMENTAL SECTION

Solvents for extraction and chromatography were of technical grade. All solvents used in reactions were freshly distilled. All other reagents were recrystallized or distilled as necessary. All reactions were performed under an atmosphere of dry nitrogen. Melting points are uncorrected. IR-FT spectra were obtained as solids in KBr or as neat oils in NaCl. Mass spectra (MS) were made by electron impact (EI) at an ionizing voltage of 70 eV or by chemical ionization (CI) and high-resolution mass spectra (HRMS) was measured by the EI method. ¹H (300, 400 MHz), ¹³C (75, 100 MHz), and ³¹P NMR (120, 160 MHz) spectra were recorded on 300 or 400 MHz spectrometers, respectively, in CDCl₃, as specified below. Chemical shifts (δ_{H}) are reported in parts per million (ppm), relative to TMS as internal standard. Chemical shifts (δ_{C}) are reported in parts per million (ppm), relative to CDCl₃, as internal standard in a broad band decoupled mode. The abbreviations used are as follows: s, singlet; d, doublet; dd, double-doublet; t, triplet; q, quartet; m, multiplet. Flash-column chromatography was carried out using commercial grades of silica gel finer than 230 mesh. Analytical thin layer chromatography (TLC) was performed on precoated silica gel 60 F₂₅₄ plates, and spot visualization was accomplished by UV light (254 nm) or KMnO₄ solution. Azirines **1** and **6** were prepared according to literature procedure.^{20b}

General Procedure for the Synthesis of Substituted Pyrrole 3 or 7. To a solution of NaH (5.5 mmol) in dry THF (15 mL) under nitrogen atmosphere was added a solution of alkyl 2-oxobutanoate **2** (5.5 mmol). The mixture was stirred at room temperature for 1 h. A solution of 2*H*-azirinyphosphine oxides **1** (R = Ph) or -phosphonates **6** (R = OEt) (5.0 mmol) in dry THF (6 mL) was added slowly under nitrogen atmosphere. The mixture was stirred under reflux in THF for 2 or 5 h until TLC showed the disappearance of azirine. The NaH remainder was neutralized with a saturated solution of NH₄Cl, and the solvent was evaporated under vacuum. The crude reaction was dissolved with CH₂Cl₂ (25 mL) and washed with water (3 × 10 mL). The organic layer was dried over anhydrous MgSO₄ and filtered, and the solvent was evaporated under vacuum. The crude product was purified by chromatography using silica gel (hexane/ethyl acetate) to yield the compounds **3** or **7** as white solid or as yellow oil.

Methyl 5-Diphenylphosphoryl-2,4-dimethyl-1*H*-pyrrole-3-carboxylate (3a). Compound **3a** was obtained as a white solid from 2*H*-azirine **1a** using the general procedure (1059 mg, 60%): mp 236–237 °C; ¹H NMR (CD₃OD) δ 1.89 (d, ⁴J_{PH} = 1.5 Hz, 3H, CH₃), 2.42 (s, 3H, CH₃), 3.72 (s, 3H, OCH₃), 7.36–7.69 (m, 10H, H-*arom*), 10.41 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 12.8, 13.9, 50.6, 113.3 (d, ³J_{PC} = 11.1 Hz), 115.4 (d, ¹J_{PC} = 133.0 Hz), 128.4–133.2, 130.7 (d, ²J_{PC} = 14.6 Hz), 141.0 (d, ⁴J_{PC} = 8.1 Hz) 166.1; ³¹P NMR (CD₃OD) δ 21.9; IR (NaCl) ν_{max} 3154, 3081, 3037, 2958, 1698, 1438, 1169, 1125 cm⁻¹; HRMS (ESI) *m/z* calcd for C₂₀H₂₁NO₃P [M⁺ + H] 354.1254, found 354.1253.

Ethyl 5-Diphenylphosphoryl-2,4-dimethyl-1*H*-pyrrole-3-carboxylate (3b). Compound **3b** was obtained as a white solid from 2*H*-azirine **1b** using the general procedure (1101 mg, 60%): mp 241–242 °C; ¹H NMR (CD₃OD) δ 1.27 (t, ³J_{HH} = 7.2 Hz, 3H, CH₃), 1.91 (s, 3H, CH₃), 2.45 (s, 3H, CH₃), 4.21 (q, ³J_{HH} = 7.2 Hz, 2H, OCH₂), 7.22–7.67 (m, 10H, CH-*arom*), 10.44 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 12.8, 14.2, 14.4, 59.3, 113.6 (d, ³J_{PC} = 11.6 Hz), 115.4 (d, ¹J_{PC} = 133.0 Hz), 128.5–133.3, 130.7 (d, ²J_{PC} = 14.6 Hz), 140.9 (d, ⁴J_{PC} = 8.1 Hz), 165.9; ³¹P NMR (CD₃OD) δ 21.9; IR (NaCl) ν_{max} 3136, 3087, 3029, 2980, 1699, 1436, 1160, 1116 cm⁻¹; HRMS (ESI) *m/z* calcd for C₂₁H₂₃NO₃P [M⁺ + H] 368.1416, found 368.1425.

Methyl 5-Diphenylphosphoryl-4-ethyl-2-methyl-1*H*-pyrrole-3-carboxylate (3c). Compound **3c** was obtained as a white solid from 2*H*-azirine **1c** using the general procedure (1376 mg, 75%): mp 245–246 °C; ¹H NMR (CD₃OD) δ 0.57 (t, ³J_{HH} = 7.3 Hz, 3H, CH₃), 2.37 (q, ³J_{HH} = 7.3 Hz, 2H, CH₂), 2.49 (s, 3H, CH₃), 3.77 (s, 3H, OCH₃), 7.40–7.68 (m, 10H, CH-*arom*), 11.21 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 14.2, 14.6, 19.9, 50.5, 112.1 (d, ³J_{PC} = 11.1 Hz),

114.5 (d, ¹J_{PC} = 133.0 Hz), 128.4–133.5, 137.2 (d, ²J_{PC} = 15.1 Hz), 141.7 (d, ⁴J_{PC} = 8.6 Hz), 168.8; ³¹P NMR (CD₃OD) δ 22.5; IR (NaCl) ν_{max} 3155, 3082, 2958, 1698, 1169, 1127 cm⁻¹; HRMS (ESI) *m/z* calcd for C₂₁H₂₃NO₃P [M⁺ + H] 368.1416, found 368.1418.

Methyl 5-Diethoxyphosphoryl-2,4-dimethyl-1*H*-pyrrole-3-carboxylate (7a). Compound **7a** was obtained as a yellow oil from 2*H*-azirine **6a** using the general procedure (867 mg, 60%): R_f 0.30 (ethyl acetate); ¹H NMR (CD₃OD) δ 1.23 (t, ³J_{HH} = 7.0 Hz, 6H, CH₃), 2.30 (d, ⁴J_{PH} = 1.8 Hz, 3H, CH₃), 2.45 (s, 3H, CH₃), 3.74 (s, 3H, OCH₃), 3.91–4.06 (m, 4H, OCH₂) 10.36 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 11.9 (d, ⁴J_{PC} = 3.0 Hz), 13.9 (d, ²J_{PC} = 6.6 Hz), 16.2, 50.6 (d, ⁶J_{PC} = 1.5 Hz), 62.1, 112.7 (d, ¹J_{PC} = 228.6 Hz), 113.1 (d, ³J_{PC} = 15.1 Hz), 132.0 (d, ²J_{PC} = 17.1 Hz), 140.7 (d, ⁴J_{PC} = 11.1 Hz) 166.0 (d, ⁴J_{PC} = 2.5 Hz); ³¹P NMR (CD₃OD) δ 11.7; IR (NaCl) ν_{max} 3181, 3110, 2980, 2918, 1694, 1018 cm⁻¹; HRMS (ESI) *m/z* calcd for C₁₂H₂₁NO₃P [M⁺ + H] 290.1157, found 290.1160.

Methyl 5-Diethoxyphosphoryl-2-methyl-4-phenyl-1*H*-pyrrole-3-carboxylate (7b). Compound **7b** was obtained as a white solid from 2*H*-azirine **1b** using the general procedure (1668 mg, 95%): mp 157–158 °C; ¹H NMR (CD₃OD) δ 1.11 (t, ³J_{HH} = 7.2 Hz, 6H, CH₃), 3.09 (d, ⁵J_{PH} = 4.6 Hz, 3H, CH₃), 3.60 (s, 3H, OCH₃), 3.83 (dq, ³J_{PH} = 28.5 Hz, ³J_{HH} = 7.2 Hz, 4H, OCH₂), 7.33 (s, 5H, H-*arom*), 11.40 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 13.7, 15.9, 50.5, 62.1, 112.8 (d, ³J_{PC} = 14.1 Hz), 113.6 (d, ¹J_{PC} = 228.6 Hz), 126.9–134.6, 135.5 (d, ²J_{PC} = 16.6 Hz), 140.6 (d, ³J_{PC} = 11.1 Hz) 165.4 (d, ⁴J_{PC} = 2.5 Hz); ³¹P NMR (CD₃OD) δ 10.3; IR (NaCl) ν_{max} 3155, 3101, 2980, 1698, 1204, 1014 cm⁻¹; HRMS (ESI) *m/z* calcd for NaC₁₇H₂₂NO₃P [M⁺ + Na] 374.1133, found 374.1137.

General Procedure for the Synthesis of Substituted Pyrrole 9 and 10. To a solution of NaH (5.5 mmol) in dry THF (15 mL) at 0 °C under nitrogen atmosphere was added a solution of diethyl malonate **8a** (5.5 mmol). The mixture was stirred at the same temperature for 1 h. A solution of 2*H*-azirinyphosphine oxides **1** (R = Ph) or -phosphonates **6** (R = OEt₂) (5 mmol) in dry THF (6 mL) was slowly added at 0 °C under nitrogen atmosphere. The mixture was stirred at room temperature for 2 or 5 h until TLC showed the disappearance of azirine. The NaH remainder was neutralized with a saturated solution of NH₄Cl. The crude reaction was extracted with CH₂Cl₂ (3 × 10 mL) and washed with water (3 × 10 mL). The organic layer was dried over anhydrous MgSO₄ and filtered, and the solvent was evaporated under vacuum. The crude product was purified by crystallization from CH₂Cl₂/hexane 1/1 or chromatography using silica gel hexane/ethyl acetate 1/1 to yield the compound **9** or **10** as a brown solid or as a colorless oil.

Methyl 5-Diphenylphosphoryl-2-hydroxy-4-methyl-1*H*-pyrrole-3-carboxylate (9a). Compound **9a** was obtained as a brown solid from 2*H*-azirine **1a** as described in the general procedure (1236 mg, 67%): mp 225–226 °C; ¹H NMR (CD₃OD) δ 1.32 (t, ³J_{HH} = 7.2 Hz, 3H, CH₃), 1.98 (d, ⁴J_{PH} = 1.9 Hz, 3H, CH₃) 4.30 (q, ³J_{HH} = 7.2 Hz, 2H, OCH₂), 7.41–7.70 (m, 10H, CH-*arom*), 9.60 (s, 1H, OH), 9.92 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 12.5, 14.4, 60.1, 95.1 (d, ³J_{PC} = 10.6 Hz), 108.7 (d, ¹J_{PC} = 136.5 Hz), 128.3 (d, ²J_{PC} = 13.1 Hz), 128.5–133.3, 156.3 (d, ⁴J_{PC} = 10.6 Hz), 168.4; ³¹P NMR (CD₃OD) δ 20.9; IR (NaCl) ν_{max} 3279, 3056, 2923, 2762, 1717, 1650, 1192, 1120 cm⁻¹; HRMS (ESI) *m/z* calcd for NaC₂₀H₂₀NO₄P [M⁺ + Na] 392.1028, found 392.1024.

Ethyl 5-Diphenylphosphoryl-4-ethyl-2-hydroxy-1*H*-pyrrole-3-carboxylate (9b). Compound **9b** was obtained as a brown solid from 2*H*-azirine **1b** as described in the general procedure (1379 mg, 72%) as a brown solid: mp 231–232 °C; ¹H NMR (CD₃OD) δ 0.71 (t, ³J_{HH} = 6.6 Hz, 3H, CH₃), 1.32 (t, ³J_{HH} = 7.0 Hz, 3H, CH₃), 2.35 (q, ³J_{HH} = 6.6 Hz, 2H, CH₂), 4.30 (q, ³J_{HH} = 7.0 Hz, 2H, OCH₂), 7.27–7.80 (m, CH-*arom*), 9.64 (s, 1H, OH), 10.04 (s, 1H, NH); ¹³C NMR (CD₃OD) δ 14.2, 14.8, 19.8, 60.0, 94.0 (d, ³J_{PC} = 10.6 Hz), 107.6 (d, ¹J_{PC} = 136.0 Hz), 128.4–132.0, 133.5, 134.9 (d, ²J_{PC} = 13.6 Hz), 156.7 (d, ³J_{PC} = 11.1 Hz), 168.1; ³¹P NMR (CD₃OD) δ 21.4; IR (NaCl) ν_{max} 3292, 3136, 2980, 2900, 1654, 1200, 1120 cm⁻¹; HRMS (ESI) *m/z* calcd for C₂₁H₂₃NO₄P [M⁺ + H] 384.1365, found 384.1366.

Ethyl 5-Diethoxyphosphoryl-4-ethyl-2-hydroxy-1H-pyrrole-3-carboxylate (10). Compound 10 was obtained as a colorless oil from 2H-azirine 6a as described in the general procedure (1037 mg, 65%): R_f 0.44 (ethyl acetate); $^1\text{H NMR}$ (CD_3OD) δ 1.08 (t, $^3J_{\text{HH}} = 7.3$ Hz, 3H, CH_3), 1.27 (t, $^3J_{\text{HH}} = 7.0$ Hz, 6H, CH_3), 1.28 (t, $^3J_{\text{HH}} = 7.3$ Hz, 3H, CH_3), 2.67 (q, $^3J_{\text{HH}} = 7.3$ Hz, 2H, CH_2), 4.02 (dq, $^3J_{\text{PH}} = 23.8$ Hz, $^3J_{\text{HH}} = 7.3$ Hz, 4H, OCH_2), 4.27 (q, $^3J_{\text{HH}} = 7.0$ Hz, 2H, OCH_2) 9.62 (s, 1H, OH), 9.89 (s, 1H, NH); $^{13}\text{C NMR}$ (CD_3OD) δ 14.5, 15.7, 16.4, 19.8, 60.3, 62.3, 94.1 (d, $^2J_{\text{PC}} = 14.1$ Hz), 104.7 (d, $^1J_{\text{PC}} = 235.2$ Hz), 135.7 (d, $^3J_{\text{PC}} = 16.6$ Hz), 156.4 (d, $^4J_{\text{PC}} = 15.1$ Hz), 168.5; $^{31}\text{P NMR}$ (CD_3OD) δ 12.1; IR (NaCl) ν_{max} 3279, 3074, 2980, 1721, 1663, 1232, 1014 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{13}\text{H}_{23}\text{NO}_6\text{P}$ [$\text{M}^+ + \text{H}$] 320.1258, found 320.1253.

General Procedure for the Synthesis of α -Aminoalkylphosphine Oxides 14 and -phosphonate 15. To a solution of NaH (5.5 mmol) in dry THF (15 mL) at 0 °C under nitrogen atmosphere was added a solution of diethyl 2-phenylmalonate 8 (5.5 mmol). The mixture was stirred at the same temperature for 1 h. A solution of 2H-azirinyolphosphine oxides 1 (R = Ph) or -phosphonates 6 (R = OEt) (5 mmol) in dry THF (6 mL) was added slowly at 0 °C under nitrogen atmosphere. The mixture was stirred at room temperature for 2 or 5 h until TLC showed the disappearance of azirine. The NaH remainder was neutralized with a saturated solution of NH_4Cl , and the solvent was evaporated under vacuum. The crude reaction was dissolved with CH_2Cl_2 (25 mL) and washed with water (3×10 mL). The organic layer was dried over anhydrous MgSO_4 and filtered, and the solvent was evaporated under vacuum. The crude product was purified by chromatography using silica gel (hexane/ethyl acetate) to yield the compounds 14 or 15 as a white solid.

Ethyl 4-(Diphenylphosphoryl)-4-((ethoxycarbonyl)amino)-3-methyl-2-phenylbut-2-enoate (14a). Compound 14a was obtained as a white solid from 2H-azirine 1a as described in the general procedure (1227 mg, 50%): mp 93–94 °C; $^1\text{H NMR}$ (CD_3OD) δ 1.07–1.26 (m, $^3J_{\text{HH}} = 7.2$ Hz, 6H, CH_3), 2.27 (s, 3H, CH_3), 3.97–4.21 (m, $^3J_{\text{HH}} = 7.2$ Hz, 4H, OCH_2), 5.58 (t, $^2J_{\text{PH}} = 9.2$ Hz, 1H, CH-P), 6.30 (d, $^3J_{\text{HH}} = 3.8$ Hz, 1H, NH), 6.81–7.91 (m, 15H, CH-Arom); $^{13}\text{C NMR}$ (CD_3OD) δ 13.8, 13.9, 17.1, 52.3 (d, $^1J_{\text{PC}} = 73.0$ Hz), 60.5, 61.1, 127.4–132.6, 134.8, 135.8, 155.6 (d, $^3J_{\text{PC}} = 7.6$ Hz), 167.9; $^{31}\text{P NMR}$ (CD_3OD) δ 35.1; IR (NaCl) ν_{max} 3203, 3056, 2976, 1708, 1534, 1249, 1196 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{31}\text{NO}_5\text{P}$ [$\text{M}^+ + \text{H}$] 492.1934, found 492.1934.

Ethyl 3-((Diphenylphosphoryl)((ethoxycarbonyl)amino)-methyl)-2-phenylpent-2-enoate (14b). Compound 14b was obtained as a white solid from 2H-azirine 1b as described in the general procedure (1515 mg, 60%): mp 122–123 °C; $^1\text{H NMR}$ (CD_3OD) δ 1.08–1.22 (m, $^3J_{\text{HH}} = 7.0$ Hz, 9H, CH_3), 2.76 (dq, $^4J_{\text{PH}} = 36.8$ Hz, $^3J_{\text{HH}} = 7.0$ Hz, 2H, CH_2), 3.99–4.21 (m, $^3J_{\text{HH}} = 7.0$ Hz, 4H, OCH_2), 5.57 (t, $^2J_{\text{PH}} = 9.5$ Hz, 1H, CH-P), 6.18 (s, 1H, NH), 6.74–7.95 (m, 15H, CH-Arom); $^{13}\text{C NMR}$ (CD_3OD) δ 13.8, 14.2, 14.8, 23.9, 52.6 (d, $^1J_{\text{PC}} = 73.0$ Hz), 60.4–61.5, 127.5–131.9, 135.1, 141.3, 155.6 (d, $^2J_{\text{PC}} = 9.1$ Hz), 167.7; $^{31}\text{P NMR}$ (CD_3OD) δ 35.4; IR (NaCl) ν_{max} 3430, 3061, 2967, 2927, 1472, 1436, 1196, 1120 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{29}\text{H}_{33}\text{NO}_5\text{P}$ [$\text{M}^+ + \text{H}$] 506.2096, found 506.2106.

Ethyl 4-(Diethoxyphosphoryl)-4-((ethoxycarbonyl)amino)-3-methyl-2-phenylbut-2-enoate (15). Compound 15 was obtained as a white solid from 2H-azirine 6a as described in the general procedure (961 mg, 45%): mp 80–81 °C; $^1\text{H NMR}$ (CD_3OD) δ 1.22 (t, $^3J_{\text{HH}} = 7.1$ Hz, 6H, CH_3), 1.29 (t, $^3J_{\text{HH}} = 7.0$ Hz, 6H, CH_3), 2.11 (d, $^4J_{\text{PH}} = 3.2$ Hz, 3H, CH_3), 3.88–4.31 (m, 8H, OCH_2), 4.90 (dd, $^2J_{\text{PH}} = 22.8$ Hz, $^3J_{\text{HH}} = 9.1$ Hz, 1H, CH-P), 5.66 (s, 1H, NH), 7.28–7.56 (m, 5H, CH-Arom); $^{13}\text{C NMR}$ (CD_3OD) δ 14.0, 14.4, 16.0, 16.2 (d, $^3J_{\text{PC}} = 12.6$ Hz), 50.8 (d, $^1J_{\text{PC}} = 150.6$ Hz), 60.7–66.7, 127.7–129.5, 135.0 (d, $^2J_{\text{PC}} = 12.1$ Hz), 135.7, 136.9, 155.3 (d, $^3J_{\text{PC}} = 11.1$ Hz), 168.0 (d, $^4J_{\text{PC}} = 1.5$ Hz); $^{31}\text{P NMR}$ (CD_3OD) δ 21.1; IR (NaCl) ν_{max} 3244, 2985, 1708, 1530, 1499, 1218, 1022 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{31}\text{NO}_7\text{P}$ [$\text{M}^+ + \text{H}$] 428.1838, found 428.1840.

General Procedure for the Synthesis of Substituted Pyrroles 17 and 18. To a solution of NaH (5.5 mmol) in dry THF (15 mL) under nitrogen atmosphere was added a solution of substituted

phenylmalonate 8 (5 mmol). The mixture was stirred with reflux in THF for 1–2 h until TLC showed the disappearance of compound 14 or 15. The NaH remainder was neutralized with a saturated solution of NH_4Cl , and the solvent was evaporated under vacuum. The crude reaction was dissolved with CH_2Cl_2 (25 mL) and washed with water (3×10 mL). The organic layer was dried over anhydrous MgSO_4 and filtered, and the solvent was evaporated under vacuum. The crude product was purified by chromatography using silica-gel hexane/ethyl acetate 1/1 to yield the compounds 17 or 18 as a colorless or a pale yellow oil.

5-(Diphenylphosphoryl)-3-methyl-4-phenyl-1H-pyrrol-2-(5H)-one (17a). Compound 17a was obtained as a colorless oil from 14a as described in the general procedure (1548 mg, 83%): $R_f = 0.20$ (ethyl acetate); $^1\text{H NMR}$ (CD_3OD) δ 2.19 (d, $^4J_{\text{PH}} = 2.2$ Hz, 3H, CH_3), 5.19 (d, $^2J_{\text{PH}} = 14.2$ Hz, 1H, CH-P), 6.41 (s, 1H, NH), 6.99–7.92 (m, 15H, CH-Arom); $^{13}\text{C NMR}$ (CD_3OD) δ 14.8, 61.3 (d, $^1J_{\text{PC}} = 72.0$ Hz), 125.3–133.0, 134.3 (d, $^2J_{\text{PC}} = 6.0$ Hz), 150.5 (d, $^3J_{\text{PC}} = 5.0$ Hz), 172.9; $^{31}\text{P NMR}$ (CD_3OD) δ 29.9; IR (NaCl) ν_{max} 3176, 3065, 1721, 1690, 1441, 1178 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{23}\text{H}_{21}\text{NO}_2\text{P}$ [$\text{M}^+ + \text{H}$] 374.1310, found 374.1311.

5-(Diphenylphosphoryl)-3-ethyl-4-phenyl-1H-pyrrol-2-(5H)-one (17b). Compound 17b was obtained as a pale yellow oil from 14b as described in the general procedure: (1355 mg, 70%): R_f 0.22 (ethyl acetate); $^1\text{H NMR}$ (CD_3OD) δ 1.16 (t, $^3J_{\text{HH}} = 7.5$ Hz, 3H, CH_3), 2.62 (q, $^3J_{\text{HH}} = 7.5$ Hz, 2H, CH_2), 5.26 (d, $^2J_{\text{PH}} = 14.5$ Hz, 1H, CH-P), 6.91–7.86 (m, 15H, CH-Arom); $^{13}\text{C NMR}$ (CD_3OD) δ 13.7, 21.4, 58.7 (d, $^1J_{\text{PC}} = 72.5$ Hz), 125.4–132.8, 133.8 (d, $^2J_{\text{PC}} = 5.5$ Hz), 156.3 (d, $^4J_{\text{PC}} = 4.5$ Hz), 173.2; $^{31}\text{P NMR}$ (CD_3OD) δ 30.1; IR (NaCl) ν_{max} 3176, 3065, 2967, 2932, 2869, 1677, 1432, 1196 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{24}\text{H}_{23}\text{NO}_2\text{P}$ [$\text{M}^+ + \text{H}$] 388.1466, found 388.1474.

5-(diethoxyphosphoryl)-3-methyl-4-phenyl-1H-pyrrol-2-(5H)-one 18. Compound 18 was obtained as a pale yellow oil from 15 as described in the general procedure (1.452 g, 94%): R_f 0.16 (ethyl acetate); $^1\text{H NMR}$ (CD_3OD) δ 1.32 (t, $^3J_{\text{HH}} = 7.0$ Hz, 6H, CH_3), 2.28 (d, $^4J_{\text{PH}} = 2.4$ Hz, 3H, CH_3), 4.40 (q, $^3J_{\text{HH}} = 7.0$ Hz, 4H, OCH_2), 5.45 (d, $^2J_{\text{PH}} = 18.6$ Hz, 1H, CH-P), 7.25–7.69 (m, 6H, H-Arom y NH); $^{13}\text{C NMR}$ (CD_3OD) δ 14.5, 16.4 (d, $^3J_{\text{PC}} = 4.0$ Hz), 58.5 (d, $^1J_{\text{PC}} = 152.1$ Hz), 63.5, 128.1–129.4, 130.8 (d, $^4J_{\text{PC}} = 2.0$ Hz), 133.9 (d, $^2J_{\text{PC}} = 8.1$ Hz), 148.0 (d, $^3J_{\text{PC}} = 7.6$ Hz), 173.1 (d, $^3J_{\text{PC}} = 2.0$ Hz); $^{31}\text{P NMR}$ (CD_3OD) δ 18.1; IR (NaCl) ν_{max} 3199, 3065, 2980, 1686, 1245, 1009, 729 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{21}\text{NO}_4\text{P}$ [$\text{M}^+ + \text{H}$] 310.1203, found 310.1208.

■ ASSOCIATED CONTENT

📄 Supporting Information

$^1\text{H NMR}$ and $^{13}\text{C NMR}$ for compounds 3a–c, 7a,b, 9a,b, 10, 14a,b, 15, 17a,b, and 18. This material is available free of charge via the Internet at <http://pubs.acs.org/>

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: francisco.palacios@ehu.es

■ ACKNOWLEDGMENTS

We thank the Dirección General de Investigación del Ministerio de Ciencia e Innovación (MCINN, Madrid DGI, CTQ2009-12156BQU) and the Universidad del País Vasco - Departamento de Educación Universidades e Investigación of Gobierno Vasco (UPV, GIU/09/57; IT-422-10) for support of this work. A.V.d.B. thanks the Ministerio de Educación (Madrid) for a predoctoral fellowship. We also thank SGiker technical support for NMR spectra (MICINN, GV/EJ, and European Social Found).

REFERENCES

- (1) For reviews on azirines see: (a) Padwa, A. *Adv. Heterocycl. Chem.* **2010**, *99*, 1–31. (b) Lemos, A. *Molecules* **2009**, *14*, 4098–4119. (c) Pinho e Melo, T. M. V. D.; d'A Rocha Gonsalves, A. M. *Curr. Org. Synth.* **2004**, *1*, 275–292. (d) Gilchrist, T. L. *Aldrichim. Acta* **2001**, *34*, 51–55. (e) Palacios, F.; Ochoa de Retana, A. M.; Martínez de Marigorta, E.; de los Santos, J. M. *Eur. J. Org. Chem.* **2001**, 2401–2414.
- (2) For recent contributions, see: (a) Khlebnikov, A. F.; Novikov, M. S.; Petrovskii, P. P.; Stoeckli-Evans, H. *J. Org. Chem.* **2011**, *76*, 5384–5389. (b) Samaresh, J.; Clements, M. D.; Sharp, B. K.; Zheng, N. *Org. Lett.* **2010**, *12*, 3736–3739. (c) Candito, D. A.; Lautens, M. *Org. Lett.* **2010**, *12*, 3312–3315. (d) Greazler, S.; Stevens, K. L. *Org. Synth.* **2009**, *86*, 18–27. (e) Patonay, T.; Jeko, J.; Juhasz-Toth, E. *Eur. J. Org. Chem.* **2008**, 1441–1448. (f) Zhi, H.; Yudin, A. K. *Angew. Chem., Int. Ed.* **2010**, *49*, 1607–1610. (g) Mawad, N.; Ghorbani-Salman, F.; Linden, A.; Heimgartner, H. *Helv. Chim. Acta* **2010**, *93*, 2326–2346. (h) Budzowski, A.; Linden, A.; Heimgartner, H. *Helv. Chim. Acta* **2008**, *91*, 1471–1488.
- (3) For reviews, see: (a) Russel, J. S.; Pelkey, E. T.; Yoon-Miller, S. J. *Prog. Heterocycl. Chem.* **2011**, *22*, 143–180. (b) Trofimov, B. A.; Mikhaleva, A. I.; Schmidt, E. Yu.; Sobenina, L. N. *Adv. Heterocycl. Chem.* **2010**, *99*, 209–254. (c) Balme, G. *Angew. Chem., Int. Ed.* **2004**, *43*, 6238–6241. (d) Joule, J. A.; Mills, K. *Heterocyclic Chemistry*; Blackwell Science: Oxford, 2000. (e) *Pyrrroles*; Jones, R. A., Ed.; The Chemistry of Heterocyclic Compounds; Wiley: New York, 1996; Vol. 48, Part I. (f) Gossauer, A. *Pyrrrole*; Houben-Weyl, Thieme: Stuttgart, 1994; Vol. E6a/1, p 556.
- (4) (a) Della Pina, C.; Falletta, E.; Rossi, M. *Catal. Today* **2011**, *160*, 11–27. (b) Lee, C. F.; Yang, L. M.; Hwu, T. Y.; Feng, A. S.; Tseng, J. C.; Luh, T. Y. *J. Am. Chem. Soc.* **2000**, *122*, 4992–4993.
- (5) (a) Fürstner, A. *Angew. Chem., Int. Ed.* **2003**, *42*, 3582–3603. (b) Liu, J. H.; Yang, Q. C.; Mark, T. C. W.; Wong, H. N. C. *J. Org. Chem.* **2000**, *65*, 3587–3595. (c) Boger, D. L.; Boyce, C. W.; Labroli, M. A.; Sehon, C. A.; Jin, Q. *J. Am. Chem. Soc.* **1999**, *121*, 54–62.
- (6) (a) Rivero, M. R.; Buchwald, S. L. *Org. Lett.* **2007**, *9*, 973–976. (b) Butler, M. S. *J. Nat. Prod.* **2004**, *67*, 2141–2153.
- (7) (a) Tao, H.; Hwang, I.; Boger, D. L. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 5979–5981. (b) Biava, M.; Porretta, G. C.; Poce, G.; Battilocchio, C.; Alfonso, S.; de Logu, A.; Manetti, F.; Botta, M. *ChemMedChem* **2011**, *6*, 593–599.
- (8) For excellent recent reviews, see: (a) Casiraghi, G.; Battistini, L.; Curti, C.; Rassu, G.; Zanardi, F. *Chem. Rev.* **2011**, *111*, 3076–3154. (b) Pansare, S. V.; Paul, E. K. *Chem.—Eur. J.* **2011**, *17*, 8770–8779.
- (9) For recent contributions, see: (a) Battistini, L.; Dell'Amico, L.; Sartori, A.; Curti, C.; Pelosi, G.; Casiraghi, G.; Attanasi, O. A.; Favi, G.; F. *Adv. Synt. Catal.* **2011**, *353*, 1966–1972. (b) Huang, H.; Jin, Z.; Zhu, K.; Liang, X.; Ye, J. *Angew. Chem., Int. Ed.* **2011**, *50*, 3232–3235. (c) State, K. *J. Org. Chem.* **2011**, *76*, 1472–1474. (d) Curti, C.; Battistini, L.; Ranieri, B.; Pelosi, G.; Rassu, G.; Casiraghi, G.; Zanardi, F. *J. Org. Chem.* **2011**, *76*, 2248–2252. (e) Feng, X.; Cui, H. L.; Xu, S.; Wu, L.; Chen, Y. C. *Chem.—Eur. J.* **2010**, *16*, 10309–10312. (f) Curti, C.; Battistini, L.; Zanardi, F.; Rassu, G.; Zambrano, V.; Pinna, L.; Casiraghi, G. *J. Org. Chem.* **2010**, *75*, 8681–8684. (g) Shepherd, N. E.; Tanabe, H.; Xu, Y.; Matsunaga, S.; Shibasaki, M. *J. Am. Chem. Soc.* **2010**, *132*, 3666–3667. (h) Curti, C.; Ranieri, B.; Battistini, L.; Rassu, G.; Zambrano, V.; Pelosi, G.; Casiraghi, G.; Zanardi, F. *Adv. Synt. Catal.* **2010**, *352*, 2011–2022.
- (10) For recent reviews on these procedures, see: (a) Estevez, V.; Villacampa, M.; Menendez, J. C. *Chem. Soc. Rev.* **2010**, *39*, 4402–4421. (b) Schmuck, C.; Rupprecht, D. *Synthesis* **2007**, 3095–3110.
- (11) (a) Tsuchimoto, T. *Chem.—Eur. J.* **2011**, *17*, 4064–4075. (b) Beck, E. M.; Gaunt, M. J. *Top. Curr. Chem.* **2010**, *292*, 85–121. (c) Thirumalairajan, S.; Pearce, B. M.; Thompson, A. *Chem. Commun.* **2010**, 46, 1797–1812.
- (12) (a) Van der Jeught, K.; Stevens, C. V. *Chem. Rev.* **2009**, *109*, 2672–2702. (b) Moneen, K.; Laureyn, I.; Stevens, C. V. *Chem. Rev.* **2004**, *104*, 6177–6215.
- (13) For reviews, see: (a) Engel, R. In *Handbook of Organophosphorus Chemistry*; M. Dekker, Inc.: New York, 1992. (b) Kafarski, P.; Lejezak, B. *Phosphorus Sulfur* **1991**, *63*, 193–215. (c) Hoagland, R. E. In *Biologically Active Natural Products*; Culter, H. G., Ed.; ACS Symposium Series 380; American Chemical Society: Washington DC, 1988; p 182. (d) Toy, A. D. F.; Walsh, E. N. In *Phosphorus Chemistry in Everyday Living*; American Chemical Society: Washington DC, 1987; p 333.
- (14) Davis, F. A.; Bowen, K. A.; He, X.; Velvadapu, V. *Tetrahedron* **2008**, *64*, 4174–4182.
- (15) Palacios, F.; Ochoa de Retana, A. M.; Martínez de Marigorta, E.; Rodriguez, M.; Pagalday, J. *Tetrahedron* **2003**, *59*, 2617–2623.
- (16) Bieltiens, N.; Moonen, K.; Stevens, C. V. *Chem.—Eur. J.* **2007**, *13*, 203–214.
- (17) (a) Vicario, J.; Aparicio, D.; Palacios, F. *J. Org. Chem.* **2009**, *74*, 452–455. (b) Palacios, F.; Aparicio, D.; López, Y.; de los Santos, J. M.; Alonso, C. *Eur. J. Org. Chem.* **2005**, 1142–1147. (c) Palacios, F.; Ochoa de Retana, A. M.; Pagalday, J. *Eur. J. Org. Chem.* **2003**, 913–919. (d) de los Santos, J. M.; Ignacio, R.; Aparicio, D.; Palacios, F.; Ezpeleta, J. M. *J. Org. Chem.* **2009**, *74*, 3444–3448.
- (18) (a) Palacios, F.; Ochoa de Retana, A. M.; Fernández de Trocóniz, G.; Pascual, S.; Ezpeleta, J. M. *Eur. J. Org. Chem.* **2010**, 6618–6626. (b) Palacios, F.; Ochoa de Retana, A. M.; Oyarzábal, J.; Pascual, S.; Fernández de Trocóniz, G. *J. Org. Chem.* **2008**, *73*, 4568–4573. (c) Palacios, F.; Ochoa de Retana, A. M.; Pascual, S.; Oyarzábal, J. *J. Org. Chem.* **2004**, *69*, 8767–8774.
- (19) (a) Palacios, F.; Ochoa de Retana, A. M.; Pascual, S.; López de Munáin, R.; Oyarzábal, J.; Ezpeleta, J. M. *Tetrahedron* **2005**, *61*, 1087–1094. (b) Palacios, F.; Alonso, C.; Rodríguez, M.; Martínez de Marigorta, E.; Rubiales, G. *Eur. J. Org. Chem.* **2005**, 1795–1804.
- (20) (a) Palacios, F.; Aparicio, D.; Ochoa de Retana, A. M.; de los Santos, J. M.; Gil, J. I.; Alonso, J. M. *J. Org. Chem.* **2002**, *67*, 7283–7288. (b) Palacios, F.; Ochoa de Retana, A. M.; Gil, J. I.; Ezpeleta, J. M. *J. Org. Chem.* **2000**, *65*, 3213–3217.
- (21) (a) Palacios, F.; Ochoa de Retana, A. M.; Alonso, J. M. *J. Org. Chem.* **2006**, *71*, 6141–6148. (b) Palacios, F.; Aparicio, D.; Ochoa de Retana, A. M.; de los Santos, J. M.; Gil, J. I.; López de Munáin, R. *Tetrahedron: Asymmetry* **2003**, *14*, 689–700.
- (22) (a) Palacios, F.; Ochoa de Retana, A. M.; Gil, J. I.; López de Munáin, R. *Org. Lett.* **2002**, *4*, 2405–2408. (b) Palacios, F.; Ochoa de Retana, A. M.; Gil, J. I.; Alonso, J. M. *Tetrahedron: Asymmetry* **2002**, *13*, 2525–2541. (c) Palacios, F.; Ochoa de Retana, A. M.; Gil, J. I.; Alonso, J. M. *Tetrahedron* **2004**, *60*, 8937–8947. (d) Palacios, F.; Ochoa de Retana, A. M.; Alonso, J. M. *J. Org. Chem.* **2005**, *70*, 8895–8901.
- (23) Padwa, A.; Stengel, T. *Tetrahedron Lett.* **2004**, *45*, 5991–5993.
- (24) Piquet, V.; Baceiredo, A.; Gornitzka, H.; Dahan, F.; Bertrand, G. *Chem.—Eur. J.* **1997**, *3*, 1757–1764.
- (25) A bicyclic intermediate **16** (Scheme 4) generated from **11** followed by ring opening of both four and three membered heterocycles may also explain the formation of vinylogous derivatives **14** and **15**.
- (26) (a) Palacios, F.; Vicario, J.; Maliszewska, A.; Aparicio, D. *J. Org. Chem.* **2007**, *72*, 2682–2685. (b) Palacios, F.; Alonso, C.; de los Santos, J. M. *Chem. Rev.* **2005**, *105*, 899–931. (c) Ordoñez, M.; Rojas-Cabrera, H.; Cativiela, C. *Tetrahedron* **2009**, *65*, 17–49.
- (27) (a) Griffith, O. W. *J. Biol. Chem.* **1983**, *258*, 1591–1598. (b) Soper, T. S.; Manning, J. M.; Marcotte, P. A.; Walsh, C. T. *J. Biol. Chem.* **1977**, *252*, 1571–1575. (c) Keith, D. D.; de Bernardo, S.; Weigle, M. *Tetrahedron* **1975**, *31*, 2629–2632. (d) Coleman, J. E.; Wright, J. L. C. *J. Nat. Prod.* **2001**, *64*, 668–670. (e) Rando, R. R. *Nature* **1974**, *250*, 586–587.